Exploring Mechanisms and Morphology of QT Interval Prolongation - An Inheritable as Well as an Inducible Phenomenon
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- QTc
研究概览
简要总结
The projects will try and optimise the risk stratification for patients with Long QT syndrome by investigating how the exposure of physical and acoustic stress will affect the QT-dynamics and if beta blockers protect against arrhythmias by suppressing this dynamic QT-prolongation. Furthermore, the project will investigate the effects of Spironolactone on the QT-dynamics tested by "Brisk Standing".
First, patients are tested with known arrhythmic triggers and they are then administered thier normal dose of beta blockers. Hereafter, "Brisk Standing" test is performed and the patients are on Spironolactone for seven days. After seven days treatment the "Brisk Standing" is repeated.
详细描述
The aim of the projects is to try and optimise the risk stratification for patients with Long QT syndrome by investigating how the exposure of physical and acoustic stress will affect the QT-dynamics and if beta blockers protect against arrhythmias by suppressing this dynamic QT-prolongation. Furthermore, the project will investigate the effects of Spironolactone on the QT-dynamics tested by "Brisk Standing".
First, patients are tested with known arrhythmic triggers and they are then administered thier normal dose of beta blockers. Hereafter, "Brisk Standing" test is performed and the patients are on Spironolactone for seven days. After seven days treatment the "Brisk Standing" is repeated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Verified Long QT syndrome mutation, subtype 1 or
- •over 18 years of age
排除标准
- •Atrioventricular block,
- •Left bundle branch block,
- •Left ventricular hypertrophy,
- •Pace rhythm,
- •ST-deviations >1 mm),
- •Left ventricular ejection fraction <50 % and significant valvulopathy,
- •Unstable psychiatric disease
- •Unstable cardiovascular disease.
研究组 & 干预措施
Beta Blockers
With and without Beta Blockers
干预措施: Beta Blockers (Drug)
Spironolactone
With and without Spironolactone
干预措施: Spironolactone (Drug)
结局指标
主要结局
QTc
时间窗: 7 days
Corrected QT
次要结局
未报告次要终点
研究者
Peter Marstrand
Medical Doctor, Research Fellow
Herlev and Gentofte Hospital